356 related articles for article (PubMed ID: 22149205)
1. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
Rottem M
J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
[TBL] [Abstract][Full Text] [Related]
2. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
3. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
4. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
7. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
10. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab in patients with severe asthma: the XCLUSIVE study.
Schumann C; Kropf C; Wibmer T; Rüdiger S; Stoiber KM; Thielen A; Rottbauer W; Kroegel C
Clin Respir J; 2012 Oct; 6(4):215-27. PubMed ID: 21740532
[TBL] [Abstract][Full Text] [Related]
12. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
13. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
14. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
15. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
Busse WW; Massanari M; Kianifard F; Geba GP
Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
[TBL] [Abstract][Full Text] [Related]
17. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Shitrit D; Talker O; Metabichek A; Yaakovi I
Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
[TBL] [Abstract][Full Text] [Related]
18. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.
Massanari M; Milgrom H; Pollard S; Maykut RJ; Kianifard F; Fowler-Taylor A; Geba GP; Zeldin RK
Clin Pediatr (Phila); 2009 Oct; 48(8):859-65. PubMed ID: 19564449
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab: efficacy in allergic disease.
Spector S
Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
